Optimizacija metode plinske kromatografije-spektrometrije masa za istovremeno određivanje tetrahidrokanabinola i njegovih metabolita u urinu štakora by Nino Fuchs et al.
325
Original article DOI: 10.2478/aiht-2019-70-3352
 
Optimisation of a gas chromatography-mass spectrometry 
method for the simultaneous determination of 
tetrahydrocannabinol and its metabolites in rat urine
Nino Fuchs1*, Alena Miljanić2*, Anja Katić3, Nataša Brajenović3, Vedran Micek3, Radovan Fuchs3, 
and Irena Brčić Karačonji3
1 University Hospital Centre Zagreb, Croatia 
2 Department of Biotechnology, University of Rijeka, Croatia 
3 Institute for Medical Research and Occupational Health, Zagreb, Croatia
[Received in October 2019; Similarity Check in October 2019; Accepted in December 2019]
In order to evaluate the effect of irinotecan (IRI) on urinary elimination of delta-9-tetrahydrocannabinol (THC) in a rat 
experimental model, we developed an analytical method for the determination of the mass concentration of THC and its 
metabolites [11-hydroxy-delta-9-tetrahydrocannabinol (THC-OH) and 11-nor-9-carboxy-delta-9-tetrahydrocannabinol 
(THC-COOH)] in the urine of rats treated only with THC and treated simultaneously with THC and irinotecan. For this 
purpose, hydrolysis and solid phase extraction conditions of the investigated analytes were optimised and a gas 
chromatography-mass spectrometry (GC-MS) method was developed to determine all three analytes in rat urine. The 
most effective hydrolysis method for THC, THC-OH, and THC-COOH conjugates was so-called tandem hydrolysis by 
the β-glucuronidase enzyme from Escherichia coli at 50 °C for 2 hours and followed by alkaline hydrolysis. The proposed 
method was then applied for determining concentrations of analytes in 24-hour rat urine. THC was not detected in either 
sample, THC-OH was detected in 50 % of samples, and THC-COOH in all of the samples. Enhanced urinary THC-COOH 
excretion was noted in rats administered combined treatment compared to single THC treatment. The method described 
herein was suitable for determining the mass concentration of THC metabolites in the rat urine due to its sensitivity 
(detection limits: 0.8-1.0 μg/L), accuracy (>96 %), and precision (RSD <6 %).
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Delta-9-tetrahydrocannabinol (THC) is the main 
psychoactive substance in the plant Cannabis sativa. Lately, 
interest in the therapeutic effects of cannabinoids and the 
development of cannabinoid-derived medicine has risen, 
among others, for the purpose of alleviating symptoms such 
as diarrhoea, abdominal pain, nausea caused by 
chemotherapy, vomiting, etc. (1). Most of the aforementioned 
symptoms appear during therapy with the antitumor drug 
irinotecan (7-ethyl-10-[4-(1-piperidino)-1-piperidino] 
carbonyloxycamptothecin, IRI, CPT-11) whose primary 
purpose was chemotherapy in metastatic colorectal cancer, 
but was also proven to be effective in treating lung cancer, 
ovarian cancer, leukaemia, and malignant glioma (2). 
Although there are several conventional therapies that 
could relieve the undesired effects of antitumor drugs, we 
are faced with the growing use of cannabinoid-containing 
oral preparations administered for this purpose. Unlike 
approved and registered products that contain a standardised 
and defined dose of THC, illegal products with untested 
compositions may contain a high THC concentration. This 
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exposes patients to increased risks of harmful effects, as 
well as to potential intoxication. Apart from insufficient 
data on the therapeutic efficacy of such products, there is 
also concern regarding the potentially negative effects that 
result from the pharmacokinetic and pharmacodynamic 
interactions of cannabis’ main components with standard 
drugs (3). The quantification of cannabinoids in urine is 
necessary in pharmacokinetics studies in order to evaluate 
the potential impact of the chemotherapeutics (e.g. IRI) on 
THC metabolism. 
Due to the fast metabolism of cannabinoids, 
concentrations of THC metabolites are much higher in urine 
than in blood, so urine is considered the biological sample 
of choice for the identification and quantification of 
cannabinoids (4). Furthermore, urine as a biological 
material is relatively easy to obtain (5). 
Cannabinoids are rapidly and extensively metabolised 
by hepatic enzymes. The hydroxylation of THC yields the 
psychoact ive  component  11-hydroxy-del ta -9-
tetrahydrocannabinol (THC-OH), whereas further oxidation 
leads to the inactive 11-nor-9-carboxy-delta-9-
tetrahydrocannabinol (THC-COOH) excreted by urine 
mostly as a conjugate of glucuronic acid (6). Glucuronidation 
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is catalysed by uridine diphosphate-glucuronyltransferases 
(UGTs) (7).
The unambiguous identification of cannabinoids and 
metabolites in urine was carried out by a gas chromatograph 
(4, 8, 9) or a high performance liquid chromatograph (10-
13) coupled with a mass spectrometer as a detector. High 
performance liquid chromatography-mass spectrometry 
(HPLC-MS) enables direct conjugate detection, while the 
widely used gas chromatography-mass spectrometry (GC-
MS) requires hydrolysis of conjugates before extraction 
and analysis to quantify a total concentration (free and 
conjugated fraction) of the measured analytes. Considering 
that cannabinoids and their metabolites are present in urine 
mainly in the form of conjugates, it is necessary to hydrolyse 
these compounds.  Enzymatic hydrolysis using 
β-glucuronidases is effective for the cleavage of the 
glucuronide bond in THC and THC-OH glucuronides, while 
alkaline hydrolysis is more effective for splitting THC-
COOH glucuronides (14). In order to separate the desired 
analytes from the complex sample matrix before instrumental 
analysis, organic solvent extraction (n-hexane, ether, ethyl 
acetate, etc.) (10, 15) or solid phase extraction (SPE) (4, 8, 
9, 12, 13) were employed. 
Although rats have often been used as an experimental 
model for understanding the metabolism of drugs (16-20), 
to the best of the authors’ knowledge, urinary THC and 
metabolite detection following oral application of THC has 
not yet been studied. In the existing literature we have found 
optimised and validated chromatographic methods only for 
the determination of concentrations of cannabinoids and 
metabolites in human urine. Considering that rat urine 
differs from human urine in composition, a reliable method 
for the detection and quantification of THC and its 
metabolites in rat urine is required. Therefore, this study 
optimised the hydrolysis and extraction conditions for THC 
and its metabolites (THC-OH and THC-COOH) and 
developed and validated a GC-MS method for the 
simultaneous determination of the mass concentration of 
all three analytes in rat urine. The proposed method was 
applied to determine the THC, THC-OH, and THC-COOH 
concentration in 24-hour urine of rats treated only with THC 
or THC and IRI simultaneously.
MATERIALS AND METHODS
Chemicals and reagents
THC (Dronabinol; CAS-No. 1972-08-3) was obtained 
from THC Pharm GmbH (Frankfurt, Germany). Before 
administration, THC was dissolved in sesame oil (Bio 
Primo, Ulm, Germany). IRI (CAS-No. 100286-90-6) was 
provided as the hydrochloride trihydrate salt by LC 
Laboratories (Woburn, MA, USA). It was diluted in sterile 
0.9 % sodium chloride solution (Croatian Institute for 
Transfusion Medicine, Zagreb, Croatia). 
Analytical standards of THC (1 g/L), THC-OH 
(0.1 g/L), THC-COOH (1 g/L), and THC-COOH-d3 (1 g/L; 
internal standard) were purchased from Lipomed (Vienna, 
Austria). Intermediate stock solutions (1000 µg/L) were 
prepared by dilution with methanol and were stored at 
-20 °C. Methanol, dichloromethane, n-hexane, and ethyl 
acetate (HPLC grade) were purchased from Merck 
(Darmstadt, Germany), while glacial acetic acid (99.5 %), 
isopropyl alcohol, ammonium hydroxide, potassium 
phosphate monobasic, and potassium hydroxide were 
analytical-grade-purity products of Kemika (Zagreb, 
Croatia). N,O-bis(trimethylsilyl)trifluoroacetamide 
(BSTFA) with 1 % trimethylchlorosilane (TMCS) was 
obtained from Restek (Bellefonte, PA, USA). 
β-glucuronidases [from Escherichia coli (type IX-A, 
lyophilized powder, 1,000,000-5,000,000 units/g protein) 
and from Helix pomatia (type H-2, aqueous solution, 
≥85,000 units/mL)] were purchased from Sigma (St. Louis, 
MO, USA). A working solution of β-glucuronidase from 
E. coli was prepared by dissolving the enzyme in 0.1 mol/L 
phosphate buffer pH 6.8.
Ultra-pure water was obtained from a Milli-Q water 
purification system (Millipore, Bedford, MA, USA).
Animals
For the purpose of this study, adult male three-month 
old Wistar HsdBrlHan rats were supplied by the animal 
facility of the Institute for Medical Research and 
Occupational Health, Zagreb (Croatia). Animals were kept 
in standard clear polycarbonate cages (Ehret, Tulln, Austria) 
under pathogen-free and steady-state microenvironmental 
conditions, 12 h light/dark cycle, room temperature 20-
22 °C and humidity 40-60 %, with ad libitum access to 
standard Good Laboratory Practice (GLP) certified food 
(Complete feed for mice and rats 4RF21, Mucedola, Italy) 
and tap water. Appropriate enrichment was provided in 
animal cages. The research procedures were carried out in 
compliance with international standards and the national 
law on the protection of animal welfare. The study was 
approved by the Ethics Committee of the Institute for 
Medical Research and Occupational Health, Zagreb, Croatia 
(approval number: 100-21/16-16, 30 June 2016).
Experimental design
Adult male rats with an initial body weight of 235 g to 
249 g were randomly assigned to three groups, each 
comprising 5 animals. Rats were placed in metabolic cages 
for 24 hours for urine sample collection. 
The THC group received a single dose of 7 mg of THC/
kg body weight (bw) per os (p.o.). The IRI+THC group 
received IRI intraperitoneally (i.p.) via a single dose of 
100 mg/kg bw and immediately afterwards 7 mg/kg of THC 
p.o. The control group was treated with sesame oil p.o. and 
kept in the same conditions. For the optimisation of the 
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hydrolysis and extraction procedures, the THC group (N=5) 
received a single dose of 20 mg THC/kg bw.
The urine samples were collected into 10-mL 
polypropylene tubes over 24 hours from the moment of 
applying the tested substances. The samples from each rat 
were pooled and stored at -20 °C until analysis.
Optimised hydrolysis and solid phase extraction
The urine samples of rats (3 mL) treated with THC or 
the THC and IRI combination were mixed with 6 mL of 
0.1 mol/L phosphate buffer (pH 6.8) with the addition of 
60 µL of internal standard at concentrations of 1000 µg/L 
and 300 µL of solution of β-glucuronidase from E. coli 
(25,000 U/mL). To create a calibration curve within the 
range of 3-100 µg/L, the urine of rats from the control group 
(negative for the tested analytes) was spiked with 
appropriate aliquots of analytical standards (THC, THC-
OH, THC-COOH, and THC-COOH-d3). The mass 
concentration of the internal standard was 20 µg/L in all of 
the samples. Samples were vortex mixed and the pH of the 
samples was confirmed to be 6-7. Enzymatic hydrolysis of 
samples was performed at 50 °C for 2 hours. After the 
samples were cooled, 300 µL of 10 mol/L KOH was added, 
the samples were vortex mixed and chemical hydrolysis 
was carried out at 60 °C for 15 min. After cooling, 165 µL 
of glacial acetic acid and 2 mL of 0.1 mol/L sodium acetate 
in 5 % methanol (pH 7.0) were added to the samples. The 
measured pH values had to be within 4.5-6.5. The samples 
were centrifuged at 1400 g for 15 min and a supernatant 
was used for further procedures. 
The extraction procedure was adjusted according to  a 
previously optimised method for determining the mass 
concentration of THC-COOH in human urine (21). Bond 
Elut Certify II (Agilent Technologies, USA) columns were 
used for the solid phase extraction (SPE) of cannabinoids 
and metabolites from the urine samples. SPE columns were 
conditioned with 2 mL of methanol and 2 mL of 0.1 mol/L 
sodium acetate in 5 % methanol (pH 7.0). The sample was 
passed through a column and the column was then washed 
with 2 mL of methanol and water (1:1, v/v) mixture. After 
drying the column for 2 min using vacuum, the analytes 
were eluted with 2 mL mixture of n-hexane:ethyl 
acetate:glacial acetic acid (75:25:1, v/v/v). 
The eluents were collected in glass tubes and evaporated 
to dryness under a stream of nitrogen at room temperature. 
The dry residue was mixed with 0.5 mL of toluene and 
evaporated in the same manner. Then, 50 µL of BSTFA + 
1 % TMCS were added to the residue and the sample was 
capped, shaken, and derivatised for 15 min at 90 °C. 
To optimise the hydrolysis and extraction conditions, 
we used urine from rats that orally received a single dose 
of THC (20 mg/kg bw) and had a measurable level of all 
three analytes in their urine. The hydrolysis efficiency was 
tested by using β-glucuronidase (5000 U/mL urine) 
originating from E. coli and H. pomatia using the following 
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hydrolysis conditions: 1) 37 °C for 16 hours and 2) 50 °C 
for 2 hours. Afterwards, the obtained results were compared 
with a) chemical hydrolysis (300 µL of 10 mol/L KOH, 
60 °C for 15 min) and b) tandem hydrolysis [chemical 
hydrolysis following hydrolysis by β-glucuronidase from 
E. coli (5000 U/mL urine), at 50 °C for 2 hours]. Also, to 
evaluate hydrolysis and extraction efficiency we tested the 
volume (3 and 6 mL) of 0.1 mol/L phosphate buffer (pH 
6.8) which was added before hydrolysis, activity of 
β-glucuronidase from E. coli (5000 and 7000 U/mL), which 
is sufficient to complete hydrolysis, and the effect of 
centrifugation (room temperature, 15 min, 1400 g) on 
extraction. 
GC-MS analysis
The analyses were carried out using a Trace 1300 gas 
chromatograph (Thermo Scientific, Milan, Italy) coupled 
to a ITQ 700 ion trap mass spectrometer (Thermo Scientific, 
Austin, TX, USA). The analytes were separated on a TG-
5MS capillary column (30 m×0.25 mm ID, 0.25 μm film 
thickness, Thermo Scientific, Runcorn, UK). Helium was 
used as the carrier gas at a flow rate of 1 mL/min. Samples 
(1 μL) were injected in the programmable temperature 
vaporizing (PTV) injector which temperature was held at 
40 °C for 0.1 min and then increased to 280 °C at 3 °C/s. 
The initial oven temperature was set at 50 °C for 1 min, 
then increased to 250 °C at 50 °C/min, held for 1 min, 
increased to 280 °C at 5 °C/min, and held for 1 min. The 
transfer line temperature was set at 280 °C. The ion source 
temperature was set at 200 °C. The MS detector operated 
in electron impact ionisation mode. Three ions were 
monitored for each trimethylsilyl (TMS) derivative: THC-
TMS: m/z 371, 386, 303; THC-OH-2TMS: m/z 371, 474, 
459; THC-COOH-2TMS: m/z 371, 488, 473, and THC-
COOH-d3-2TMS: m/z 374, 491, 476. The underlined ions 
were used for quantitation.
Analytes were identified by a comparison of the 
retention time of each tested analyte with the retention time 
of the analytical standards followed by a comparison 
between the obtained mass spectrum of each tested analyte 
and the mass spectrum from our own database and NIST13 
mass spectra database. An internal standard method was 
used to quantitatively determine the analytes. 
Analytical validation of the GC-MS method
The calibration curve was prepared using the final 
experimental parameters in the concentration range of 
3-100 μg/L. The limit of detection (LOD) was calculated 
using a signal-to noise ratio of 3. Precision and accuracy 
were evaluated by analysing the blank urine samples spiked 
with two different concentrations of THC, THC-OH, and 
THC-COOH (10 and 40 μg/L) in six replicates. Accuracy 
was estimated by comparing the analyte concentration 
calculated from the calibration curve using the internal 
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standard method with the theoretical value. Precision was 
expressed as relative standard deviation (RSD).
Statistical analysis
The statistical analysis of the results was carried out 
using the Dell™ Statistica™ 13.2 software (StatSoft, Tulsa, 
OK, USA). The normality of distribution for numerical data 
was tested by Shapiro-Wilk’s test. Due to an asymmetrical 
distribution of the measured parameters, results within 
groups were expressed as median with ranges, while 
statistical significance between the groups was confirmed 
by Mann-Whitney U-test. In cases when the concentrations 
were lower than the limit of detection, values 0.5 x LOD 
were used for statistical analysis. The level of statistical 
significance was set at p<0.05.
RESULTS
The development of the analytical procedure for the 
determination of THC and metabolites in rat urine included 
the optimisation of hydrolysis and extraction conditions, 
choosing appropriate chromatographic conditions that 
enable the efficient separation of selected analytes, 
determining accuracy and precision as well as the linearity 
and sensitivity of the detector’s response. The largest peak 
area for the target ion of a particular analyte corresponded 
to the most efficient hydrolysis and extraction. All of the 
analyses were conducted in triplicate.
In the first experiment, the efficiency of two enzymes 
of different origin (from E. coli and H. pomatia) and 
different conditions: 1) 37 °C for 16 hours and 2) 50 °C for 
2 hours) for hydrolysis of conjugates of THC and 
metabolites in rat urine were tested. Hydrolysis using 
enzyme from H. pomatia did not enable the detection of 
THC, while all three analytes were detected when hydrolysis 
with enzyme from E. coli was performed using both 
hydrolysis conditions. There were no differences in the 
hydrolysis efficiency of THC and THC-OH conjugates in 
both of the applied conditions, while the efficiency of 
hydrolysis of THC-COOH conjugate was 45 % greater at 
the higher temperature over the shorter hydrolysis time. 
With this in mind, for further hydrolysis experiments, the 
enzyme from E. coli was chosen with hydrolysis conditions 
at 50 °C during 2 hours. For THC-COOH-glucuronide 
hydrolysis, alkaline hydrolysis with KOH at 60 °C for 15 
minutes was the most efficient. Combined (tandem) 
hydrolysis (enzymatic followed by alkaline) resulted in the 
most effective hydrolysis for all three conjugates (Figure 1).
In the following experiment, the effect of the amount 
of β-glucuronidase from E. coli (5000 and 7000 U/mL) on 
the hydrolysis degree of the conjugates was tested. 
Considering that the hydrolysis was equally effective using 
both amounts of enzyme, the smaller quantity of enzyme 
(5000 U/mL) was used in further experiments.
A volume of 0.1 mol/L phosphate buffer (pH 6.8; 3; and 
6 mL) added to the urine sample before enzyme hydrolysis 
was also tested. The twice lower chromatogram baseline 
noise and the 20 % larger surface of target peaks were 
achieved by using a more diluted sample (6 mL of buffer). 
An additional decrease of the chromatogram baseline noise 
(25 %) was achieved by centrifugation (15 min, 1400 g) of 
the sample before adding it to the SPE column. 
The proposed GC-MS conditions enabled the efficient 
separation of all of the tested analytes without interferences. 
IRI treatment did not influence the quality of the obtained 
Figure 1 Comparison of different types of hydrolysis for cleavage of conjugates THC, THC-OH, and THC-COOH from 24-hour rat 
urine (pooled sample of five rats that received a single dose of 20 mg of THC/kg bw orally)
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chromatograms. In order to avoid the appearance of 
additional peaks at higher column temperatures due to the 
impurities present in the complex sample matrix, after 
programmed heating to 280 °C, the column remained at 
that temperature for an additional 0.5 min.
Regressions were calculated for each of the calibration 
curves (THC, THC-OH, and THC-COOH, 3-100 μg/L) and 
they all showed good linearity with coefficients of 
determination (R2)>0.9986, p<0.01. Table 1 shows the 
results of the analytical validation of the method for 
determining the mass concentration of cannabinoids and 
metabolites in rat urine. The limits of detection were within 
the range of 0.8-1.0 µg/L, whereas accuracy exceeded 96 % 
for both of the tested concentration levels. Precision, 
expressed as relative standard deviation (RSD), was < 6 %. 
The suggested validated method was used to analyse 
10 samples of 24-hour rat urine, five of which were treated 
with a single dose of THC (7 mg/kg), while another five 
were treated with a single dose of THC (7 mg/kg) and IRI 
(100 mg/kg). The cannabinoid and metabolite concentrations 
in the 24-hour rat urine from the aforementioned two groups 
are shown in Table 2. THC was not detected in any of the 
samples, THC-OH was detected in 50 % of samples, while 
THC-COOH was found in all of the samples. A statistically 
significantly higher mass concentration of the THC-COOH 
in urine was found in the THC+IRI group compared to the 
THC group.
DISCUSSION
Urine is the most frequently used biological sample for 
the analysis of metabolites, as it is easily available and 
contains larger quantities of metabolites than other body 
fluids (6). The metabolic profile of human and rat urine is 
quite different. Rat urine is richer in amino acids and is 
therefore thicker, more viscous, and less transparent (22). 
Considering the differences in the composition of human 
and rat urine, the complexity of the sample matrix, and 
differences in metabolic rate (rats metabolise THC more 
quickly due to the larger amount of enzymes from 
cytochrome system P450 per gram of body mass) (23), it 
was necessary to optimise and validate a GC-MS procedure 
for determining the THC and metabolite concentration in 
rat urine. To the best of our knowledge, the relevant 
literature does not contain a single mention of a validated 
method involving GC-MS used for the qualitative and 
quantitative determination of the aforementioned analytes 
in rat urine.
In the first experiment, we optimised the conditions of 
glucuronide hydrolysis, as during THC metabolism, THC 
and metabolite conjugation with glucuronic acid occurs and 
glucuronides are formed (9). Having in mind the polarity 
and size of a metabolite bound in the form of a glucuronide, 
it is not possible to analyse them using gas chromatography. 
For that reason, it is necessary to separate the analyte from 
the glucuronic acid by hydrolysis process. The enzyme 
β-glucuronidase isolated from E. coli bacteria showed better 
hydrolytic activity than the same enzyme isolated from the 
H. pomatia snale. The dependence of β-glucuronidase 
activity on the source of the enzyme is in accordance with 
literature sources that point to a weak hydrolytic activity 
of enzymes from H. pomatia towards THC and THC-COOH 
glucuronides (15). We monitored the efficiency of 
enzymatic hydrolysis by β-glucuronidase from E. coli over 
two time intervals at different temperatures (16 hours at 
37 °C and 2 hours at 50 °C), non-enzymatic alkaline 
hydrolysis by potassium hydroxide, and combined (tandem) 
hydrolysis (enzyme followed by alkaline). While both 
conditions of enzymatic hydrolysis yielded similar results, 
with a slightly higher detected concentration of THC-
COOH at 50 °C during 2 hours compared to enzymatic 
hydrolysis at 37 °C during 16 hours, potassium hydroxide 
hydrolysis exhibited the highest THC-COOH concentrations 
with extremely low THC-OH and THC values, suggesting 
that potassium hydroxide does not hydrolyse the ether bond 
in THC and THC-OH glucuronides, but only the ester bond 
in the THC-COOH glucuronide (8, 15). Enzymatic 
hydrolysis is more suitable for splitting the ether bond (15). 
Combined hydrolysis was shown to be the most effective, 
after which the highest concentrations for all of the analytes 
were detected, with special emphasis on the THC-COOH 
concentration, which was higher in comparison with 
individual hydrolyses. Therefore, tandem hydrolysis, using 
the enzyme from E. coli at 50 °C during 2 hours, followed 
by alkaline hydrolysis at 60 °C during 15 min, proved to 
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Table 1 The precision, accuracy, and limit of detection in determining the mass concentrations of cannabinoids and metabolites in rat 
urine (N = 6)













N=number of replicates at each concentration level; γ – mass concentration; RSD – relative standard deviation
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be the best with the highest detected concentrations of all 
the analytes.
During hydrolysis, for purposes of urine sample 
preparation, the effect of a volume of phosphate buffer (3 
and 6 mL) added before hydrolysis to dilute the thick rat 
urine samples was examined. We concluded that greater 
dilution is more favourable for further analyses of samples 
on SPE columns, which resulted in lower chromatogram 
baseline noise and a larger surface of target peaks. The 
efficiency of extraction was also increased by sample 
centrifugation, which removes the tiny particles that 
originate from the enzymes and significantly endanger the 
quality of the chromatogram. Hydrolysis was also efficient 
with the smaller enzyme quantity (5000 U/mL) and our 
results were in accordance with the available literature (15).
GC-MS analysis of cannabinoids and metabolites in 
urine using optimised conditions of hydrolysis and 
extraction enabled an effective separation of all of the tested 
analytes. The sensitivity (LOD=0.8-1.0 µg/L), accuracy 
(>96 %), and precision (RSD<6 %) of the optimised and 
validated GC-MS method were similar to the values of these 
parameters obtained by other authors using GC-MS (8) and 
LC-MS (12, 13) for the determination of cannabinoids and 
metabolites in human urine. 
The proposed GC-MS method was used to analyse 24-
hour urine samples of rats administered only THC and THC 
in combination with IRI. Enhanced urinary THC-OH and 
THC-COOH concentrations were noted in rats administered 
combined treatment compared to single THC treatment. 
Possible explanations for such a result could be the potential 
redistribution of THC from fatty tissues into blood due to 
interaction with IRI (7), fatty tissue loss caused by IRI 
application, which also increases the free fraction of THC 
in blood available for metabolising (24), or the competition 
of THC and IRI for the same enzyme in phase II metabolism 
(conjugation with glucuronic acid mediated by UGT1A1) 
(25, 26). 
CONCLUSION
To understand changes in THC metabolism as a 
consequence of its concomitant use with different 
chemotherapeutics, it was necessary to find a suitable 
method for quantifying THC and its metabolites in 
biological samples. The GC-MS method proposed within 
this study is sensitive, accurate, and precise and therefore 
acceptable for the quantification of THC metabolites in rat 
urine. 
However, further studies are needed to elucidate the 
increase of the THC metabolites urinary concentrations in 
the concomitant use of IRI and THC.
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THC group (N = 5) IRI+THC group (N = 5)
THC ND ND
THC-OH 0.5 (ND-8.5) 1.7 (ND-9.3)
THC-COOH 16.6 (15.1-18.4) 18.7* (18.5-22)
* statistically significant difference in comparison with the THC group (p<0.05; Mann-Whitney’s U-test)
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Optimizacija metode plinske kromatografije-spektrometrije masa za istovremeno određivanje tetrahidrokanabinola 
i njegovih metabolita u urinu štakora
S ciljem procjene učinka irinotekana (IRI) na eliminaciju delta-9-tetrahidrokanabinola (THC) mokraćom u eksperimentalnom 
modelu štakora, razvili smo analitičku metodu za određivanje masene koncentracije THC-a i njegovih metabolita 
[11-hidroksi-delta-9-tetrahidrokanabinola (THC-OH) i 11-nor-9-karboksi-delta-9-tetrahidrokanabinola (THC-COOH)] 
u mokraći štakora tretiranih samo THC-om i tretiranih istodobno s THC-om i IRI-jem. U tu svrhu optimizirani su uvjeti 
hidrolize i ekstrakcije na čvrstom nosaču za ispitivane analite i razvijena je metoda plinske kromatografije-spektrometrije 
masa (GC-MS) kako bi se kvantificirala sva tri analita u mokraći štakora. Najučinkovitija metoda hidrolize za konjugate 
THC, THC-OH i THC-COOH bila je tandemska hidroliza enzimom β-glukuronidazom iz Escherichia coli na 50 ° C u 
trajanju od 2 sata koju je slijedila alkalna hidroliza. Predložena metoda je primijenjena za određivanje masene koncentracije 
analita u 24-satnom urinu štakora. THC nije detektiran ni u jednom uzorku, THC-OH je kvantificiran u 50 % uzoraka, a 
THC-COOH u svim uzorcima. Uočeno je povećano izlučivanje THC-COOH u mokraći štakora koji su tretirani 
kombinacijom THC-a i IRI-ja u usporedbi sa štakorima tretiranim samo THC-om. Opisana metoda bila je pogodna za 
određivanje masene koncentracije metabolita THC-a u mokraći štakora zbog njene osjetljivosti (granice detekcije: 0,8-1,0 
µg/L), točnosti (> 96%) i preciznosti (RSD <6%).
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